1073 related articles for article (PubMed ID: 15726516)
1. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
2. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
Thorstad WL; Haughey B; Chao KS
Semin Oncol; 2003 Dec; 30(6 Suppl 18):96-100. PubMed ID: 14727249
[TBL] [Abstract][Full Text] [Related]
4. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
5. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
[TBL] [Abstract][Full Text] [Related]
6. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
7. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J; Rosine D
Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
[TBL] [Abstract][Full Text] [Related]
8. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
de Castro G; Federico MH
Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
11. Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life.
Eisbruch A; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Anzai Y; Marsh LH; Martel MK; Ten Haken RK; Wolf GT; Ship JA
Acta Otorhinolaryngol Belg; 1999; 53(3):271-5. PubMed ID: 10635407
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy-induced salivary dysfunction.
Ship JA; Hu K
Semin Oncol; 2004 Dec; 31(6 Suppl 18):29-36. PubMed ID: 15726520
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma.
Daly ME; Lieskovsky Y; Pawlicki T; Yau J; Pinto H; Kaplan M; Fee WE; Koong A; Goffinet DR; Xing L; Le QT
Head Neck; 2007 Mar; 29(3):211-20. PubMed ID: 17111429
[TBL] [Abstract][Full Text] [Related]
15. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?
Jellema AP; Doornaert P; Slotman BJ; Leemans CR; Langendijk JA
Radiother Oncol; 2005 Nov; 77(2):164-71. PubMed ID: 16256229
[TBL] [Abstract][Full Text] [Related]
16. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
[TBL] [Abstract][Full Text] [Related]
17. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
19. Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer.
Saarilahti K; Kouri M; Collan J; Kangasmäki A; Atula T; Joensuu H; Tenhunen M
Radiother Oncol; 2006 Mar; 78(3):270-5. PubMed ID: 16564589
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]